[1]
E.-G. Dobre, “Investigating RUNX2 KO in B16 melanoma cells as a potential strategy to enhance in vivo tumor response to therapeutic approaches”, SEE J Immunol, vol. 8, no. CITIM, p. 065, Mar. 2025.